1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Mereo On The Move With Strong COPD Data And US Listing Plan

 
• By Kevin Grogan

The UK firm, boosted by promising data for acumapimod for acute exacerbations of COPD, is seeking to conduct an initial public offering in the US.

Businessman
America calling: The UK's Mereo is looking at a US listing • Source: Shutterstock

Mereo BioPharma Group PLC.'s model of acquiring then developing assets from big pharma looks to be paying dividends again, highlighted by impressive data on its chronic obstructive pulmonary disease (COPD) drug acumapimod, bought off Novartis AG, and plans to list in the US.

Last week, the UK company announced positive top-line results from a Phase II trial with acumapimod in acute exacerbations of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 
• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.